Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves’ Ophthalmopathy
source: U.S. National Library of Medicine
year: 2021
summary/abstract:The purpose of the current study is to confirm safety/tolerability and key pharmacodynamic (PD) effects that are considered to drive clinical benefit in GO patients.
Primary Outcome Measure:
• Assessment of safety by analysis of adverse events (AEs) data [ Time Frame: 7 Weeks ] AE summaries of the number and percent of participants reporting each event at least once will be generated. Other safety data will be summarized descriptively.
• Percentage change from baseline in total IgG and IgG subclasses (1-4) [ Time Frame: 7 Weeks ]
• Percentage change in levels of anti-TSHR antibodies [ Time Frame: 7 Weeks ]
Secondary Outcome Measure:
• Percent change from baseline in proptosis [ Time Frame: 7 Weeks ]
• Total number of proptosis responders [ Time Frame: 7 Weeks ]
• Pharmacokinetics (PK) Parameters of AUC (0-168 h) after first and last dose [ Time Frame: 7 Weeks ]
• Pharmacokinetics (PK) maximum concentration (Cmax) after first and last dose [ Time Frame: 7 Weeks ]
• Concentration of RVT-1401 pre-dose (Ctrough) [ Time Frame: 7 Weeks ]
• Immunogenicity determined by number of participants with positive anti-RVT-1401 antibodies and characterization of any anti-RVT-1401 antibodies to confirm neutralization potential [ Time Frame: 7 Weeks ]
read more
Related Content
-
Ask a Doctor questions about Graves’ disease, thyroid eye disease, & Hashimoto’s thyroiditishttps://www.youtube.com/watch?v=RxElrnS6...
-
Victor Maurice Elner, MD, PhDVictor Maurice Elner is a Professor of o...
-
Sensitivity and Responsiveness of the Patient-Reported TED-QOL to Rehabilitative Surgery in Thyroid Eye DiseaseWe tested the sensitivity and responsive...
-
Clinical Characteristics of Patients Requiring a Second Dose of Radioactive Iodine for the Treatment of Graves’ Di...Graves’ disease is an autoimmune condi...
-
“TED Today” Episode 3https://www.youtube.com/watch?v=NqM9kf1h...
-
Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to Focus on Thyroid Eye DiseaseFor Graves’ Disease Awareness Month in...
-
Preoperative Clinical Features of Reactivated of Graves’ Orbitopathy After Orbital DecompressionPurpose: To investigate the incidence a...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.